Navigation Links
Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results

NASHVILLE, Tenn., March 10 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced full year 2009 financial results.

"The approval and launch of Caldolor and our initial public offering made 2009 a pivotal year for Cumberland," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We are pleased to report that we achieved our objectives of remaining profitable and cash flow positive during the Caldolor launch, and that our balance sheet is now the strongest in the history of the Company."

Net Revenue:  For the year ended December 31, 2009, net revenue was $43.5 million, an increase of 24% over the same period in 2008. This growth was due primarily to an increase in volume for Acetadote® (acetylcysteine) Injection, the Company's treatment for acetaminophen overdose, as well as initial stocking from the launch of Caldolor® (ibuprofen) Injection, Cumberland's recently approved IV treatment for pain and fever. Net revenue for the three months ended December 31, 2009 was $10.7 million, compared to $9.8 million for the same period in 2008.

Operating Expenses:  Total operating expenses for the year ended December 31, 2009, were $37.8 million, compared to $27.8 million for the same period in 2008. This increase was due primarily to sales and marketing expense associated with the Caldolor launch, particularly the expansion of the Company's hospital sales force, $2.0 million in Caldolor milestone obligations, and a payroll tax expense of $1.1 million related to the exercise of non-qualified options. For the three-month period ended December 31, 2009, total operating expenses were $10.0 million, compared with $8.3 million for the corresponding period in 2008, an increase due primarily to sales and marketing costs associated with the launch of Caldolor.

Net Income:  Net income for the year ended December 31, 2009 was $3.1 million, or $0.17 per diluted share, compared to $4.8 million, or $0.29 per diluted share, for the same period in 2008. This change in earnings per share is due in part to an increase in shares outstanding from Cumberland's initial public offering in 2009. Excluding the aforementioned Caldolor milestone and payroll tax expenses, net income as adjusted for the year ended December 31, 2009, was $4.9 million, or $0.27 per diluted share.

Net income for the three months ended December 31, 2009, was $0.3 million, or $0.01 per diluted share, compared to $1.1 million, or $0.07 per diluted share, for the corresponding period in 2008.  The decrease in net income is due primarily to a $0.9 million increase in net revenues offset by a $1.7 million increase in operating expenses and increased interest expense associated with the Company's new credit facility. This change in earnings per share was due to the decrease in net income and an increase in shares outstanding from Cumberland's initial public offering.

EBITDA:  Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) for the year ended December 31, 2009 was $6.6 million compared to $8.1 million for the same period in 2008. Excluding $0.7 million of non-cash stock compensation expense, $1.1 million in payroll taxes from non-qualified stock option exercises and $2.0 million in Caldolor milestone expenses in 2009, and $0.6 million in non-cash compensation expense in 2008, adjusted EBITDA would have been $10.4 million and $8.6 million in 2009 and 2008, respectively, representing growth of 20%.

Balance Sheet:  As of December 31, 2009, Cumberland had $78.7 million in cash and cash equivalents, compared to $11.8 million for the year ended December 31, 2008. Total assets at December 31, 2009 of $103.7 million represented an increase of $72.6 million over 2008. These increases were due primarily to the net proceeds received from the Company's initial public offering. Cumberland had total debt of $19.8 million, including a current portion of $9.1 million. The Company had net accounts receivable and inventories of $6.2 million and $4.8 million, respectively, at December 31, 2009.

2009 Highlights

Caldolor Launch

In September 2009, Cumberland successfully launched Caldolor in the United States. The Company's hospital and field sales forces, comprised of 113 experienced sales professionals, are now promoting the product and Caldolor is fully stocked at wholesalers serving hospitals nationwide. The Company is working to introduce Caldolor and secure formulary approval nationally, and the product is now stocked in a number of medical facilities across the country. In addition to personal sales promotion, Cumberland is supporting the product through a multi-faceted marketing campaign, including internet and media advertising, medical society and convention presence, journal publications, and its medical information call center.

Initial Public Offering

In August 2009, Cumberland completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising $85.0 million in gross proceeds. Net proceeds to the Company were $74.8 million after commissions and offering expenses. Cumberland's common stock began trading on the NASDAQ Global Select Market on August 11, 2009, under the trading symbol "CPIX". Proceeds from the offering helped to fund the launch of Caldolor, and Cumberland's continued profitability and positive cash flow have allowed the Company to retain the majority of the proceeds for potential new acquisitions.

International Markets

In 2009, the Company announced that it entered into exclusive agreements with Phebra Pty Ltd. for commercialization of Caldolor in Australia and New Zealand, and with DB Pharm Korea for registration and commercialization of the product in South Korea. Phebra and DB Pharm Korea will be responsible for obtaining regulatory approval for Caldolor in their respective territories, and for handling ongoing regulatory requirements, product marketing, distribution and sales. Cumberland will maintain responsibility for product formulation, development and manufacturing, and will provide finished product for sale. Cumberland will receive upfront and milestone payments as well as a transfer price from the partnering companies, and will also receive royalties on any sales of Caldolor in those territories.

New Intellectual Property Initiative for Caldolor

In addition to Cumberland's issued patent for Caldolor, the Company has filed the two new patent applications based on its clinical data for the product. Cumberland's research in hospitalized patients uncovered new findings for which the Company previously filed several provisional patent applications. Cumberland has now converted two of these provisional applications to full applications, which address the effect of intravenous ibuprofen in critically-ill, hospitalized patients as well as its effect on patient blood pressure.

Recent Developments

Cumberland intends to file a supplemental New Drug Application (sNDA) for Acetadote related to the product's ability to treat acute liver failure. Cumberland originally received FDA approval for Acetadote in 2004 for the treatment of acetaminophen overdose in adults, and has since expanded the product's label with a pediatric indication in 2006 and data further supporting the product's safety in 2008. This new sNDA submission is primarily based on a recent multicenter clinical study led by investigators at the University of Texas Southwestern Medical Center. The study results demonstrate that Acetadote is both safe and effective in treating patients suffering from acute liver failure, significantly improving transplant-free survival rates and reducing the number of patients requiring liver transplant.

Supplemental Financial Information

The following table provides a reconciliation of Cumberland's reported (GAAP) statement of income to our adjusted (non-GAAP) statement of income for the period ended December 31, 2009. The adjusted statement includes certain items that management believes are infrequent or unusual in amount, and is provided to assist investors in evaluating Cumberland's current and future performance. The adjusted statement should not be considered a substitute for Cumberland's reported statement of income.

    Net income, as reported                                  $3,091,415
    Non-GAAP adjustments:
      Milestone expenses associated with the FDA
        approval of Caldolor                                  1,950,362
      Payroll tax expense associated with the
        exercise of nonqualified options                      1,093,464
      Tax impact of above adjustments*                       (1,211,138)
    Net income, as adjusted                                  $4,924,103
    Weighted-average shares outstanding - diluted            18,234,171
    Earnings per share - diluted (as reported)                    $0.17
    Earnings per share - diluted (as adjusted)                    $0.27
    *Amount calculated based on the Company's effective tax rate at
     December 31, 2009.

The following table presents a reconciliation of Cumberland's net income to EBITDA and adjusted EBITDA. The Company defines EBITDA as net income plus interest, income tax, depreciation and amortization, and presents these measures to assist investors in evaluating Cumberland's operating performance and comparing the Company's results with those of other companies. EBITDA and adjusted EBITDA should not be considered in isolation from or as a substitute for net income.

                                             Year ended
                                           December 31, 2009
    Net income                                 3,091,415
    Income tax expense                         2,024,192
    Depreciation & amortization                  816,499
    Interest (income) expense, net               693,564
    EBITDA                                     6,625,670
      Non-cash stock compensation                708,196
      Payroll taxes from stock option
       exercises                               1,093,464
      Caldolor milestone expenses              1,950,362
    Adjusted EBITDA                           10,377,692
                                               Year ended
                                           December 31, 2008
    Net income                                 4,766,249
    Income tax expense                         2,543,951
    Depreciation & amortization                  786,597
    Interest (income) expense, net               (27,979)
    EBITDA                                     8,068,818
       Non-cash stock compensation               562,704
    Adjusted EBITDA                            8,631,522

Conference Call and Webcast

A conference call and live webcast will be held on Wednesday, March 10, 2010, at 11:00 a.m. Eastern Time to discuss the Company's full year 2009 financial results.  To participate on the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 800-642-1687 (for U.S. callers) or 706-645-9291 (for international callers). The Conference ID for the rebroadcast is 58871773. The live webcast and rebroadcast can be accessed via Cumberland Pharmaceuticals' website at  

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever available in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It is the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit

About Acetadote

Acetadote is used in the emergency department to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter painkillers. It is the only approved injectable product in the United States for the treatment of acetaminophen overdose, the leading cause of poisonings presenting in emergency departments in the country(1). Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma, or where there is a history of bronchospasm. The total volume administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure, and death.  For full prescribing information, visit

About Kristalose

Kristalose is indicated for the treatment of acute and chronic constipation.  It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.  Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia.  Nausea and vomiting have been reported.  Use with caution in diabetics.  Kristalose is contraindicated in patients who require a low-galactose diet.  Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit

(1)*National Poison Data System, American Association of Poison Control Centers

Forward Looking Statements

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or a failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's Registration Statement declared effective by the SEC on August 10, 2009. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

    DECEMBER 31, 2009 AND 2008
    ASSETS                                         2009              2008
                                                   ----              ----
    Current assets:
      Cash and cash equivalents                $78,701,682       $11,829,551
      Accounts receivable, net of allowances     6,176,585         3,129,347
      Inventories                                4,822,873         1,762,776
      Prepaid and other current assets           2,746,259           481,312
      Deferred tax assets                          726,196           507,212
                 Total current assets           93,173,595        17,710,198
    Property and equipment, net                    918,412           432,413
    Intangible assets, net                       7,956,009         8,528,732
    Deferred tax assets                          1,306,514         1,000,031
    Other assets                                   369,790         3,447,813
                                                   -------         ---------
                 Total assets                 $103,724,320       $31,119,187
                                              ============       ===========
    Current liabilities:
      Current portion of long-term debt         $9,061,973        $1,250,000
      Current portion of other long-term
       obligations                                 144,828           457,915
      Accounts payable                           5,632,796         3,257,164
      Other accrued liabilities                  3,784,777         2,640,855
                                                 ---------         ---------
                 Total current liabilities      18,624,374         7,605,934
    Revolving line of credit                     1,825,951         1,825,951
    Long-term debt, excluding current portion    8,938,027         3,750,000
    Other long-term obligations, excluding
     current portion                               184,632           382,487
                                                   -------           -------
                 Total liabilities              29,572,984        13,564,372
                                                ----------        ----------
    Commitments and contingencies
    Redeemable common stock                      1,930,000                 -
    Shareholders’ equity:
      Cumberland Pharmaceuticals Inc.
       shareholders' equity:
        Convertible preferred stock – no par
         value; 3,000,000 shares authorized;
         812,749 shares issued and outstanding
         as of December 31, 2008                         -         2,604,070
        Common stock – no par value; 100,000,000
         shares authorized; 20,180,486 (1) and
         9,903,047 shares issued and outstanding
         as of December 31, 2009 and 2008,
         respectively                           67,711,746        13,500,034
        Retained earnings                        4,542,126         1,450,711
                                                 ---------         ---------
          Total shareholders’ equity            72,253,872        17,554,815
                                                ----------        ----------
    Noncontrolling interests                       (32,536)                -
                                                   -------               ---
          Total equity                          72,221,336        17,554,815
                                                ----------        ----------
                 Total liabilities and equity $103,724,320       $31,119,187
                                              ============       ===========
    (1)  Number of shares issued and outstanding represents total shares of
         common stock regardless of classification on the consolidated balance
         sheet. The number of shares of redeemable common stock as of December
         31, 2009 was 142,016.
    YEARS ENDED DECEMBER 31, 2009, 2008 AND 2007
                                            2009         2008         2007
                                            ----         ----         ----
      Net product revenue              $43,142,350  $34,889,967  $27,821,646
      Other revenue                        394,928      185,193      241,943
                                           -------      -------      -------
    Net revenues                        43,537,278   35,075,160   28,063,589
    Costs and expenses:
      Cost of products sold              4,136,541    3,045,672    2,669,628
      Selling and marketing             20,194,074   14,387,153   10,053,355
      Research and development           4,993,278    4,429,064    3,693,917
      General and administrative         7,643,070    5,139,937    4,137,942
      Amortization of product license
       right                               686,904      686,904      686,905
      Other                                106,776      104,209       96,524
                                           -------      -------       ------
    Total costs and expenses            37,760,643   27,792,939   21,338,271
                                        ----------   ----------   ----------
    Operating income                     5,776,635    7,282,221    6,725,318
    Interest income                         79,363      241,282      382,919
    Interest expense                      (772,927)    (213,303)    (639,590)
                                          --------     --------     --------
    Income before income taxes           5,083,071    7,310,200    6,468,647
    Income tax expense                  (2,024,192)  (2,543,951)  (2,424,261)
                                        ----------   ----------   ----------
    Net income                           3,058,879    4,766,249    4,044,386
    Net loss at subsidiary attributable
     to noncontrolling interests            32,536            -            -
    Net income attributable to common
     shareholders                       $3,091,415   $4,766,249   $4,044,386
                                        ==========   ==========   ==========
    Earnings per share attributable to
     common shareholders
      - Basic                                $0.22        $0.47        $0.40
      - Diluted                              $0.17        $0.29        $0.24
    Weighted-average shares outstanding
      - Basic                           14,199,479   10,142,807   10,032,083
      - Diluted                         18,234,171   16,539,662   16,581,902
    YEARS ENDED DECEMBER 31, 2009, 2008 AND 2007
                                            2009         2008         2007
                                            ----         ----         ----
    Cash flows from operating activities:
      Net income                         $3,058,879   $4,766,249   $4,044,386
      Adjustments to reconcile net income
       to net cash provided by operating
          Gain on early extinguishment of
           other long-term obligations            -      (38,577)           -
          Depreciation and amortization
           expense                          816,499      786,597      762,222
          Deferred tax (benefit) expense   (525,467)     683,914    2,230,596
          Nonemployee stock granted for
           services received                210,740      106,558      222,596
          Nonemployee stock option
           grant expense                    845,661       58,646       93,836
          Stock-based compensation –
           employee stock options           606,395      397,500      299,212
          Excess tax benefit derived from
           exercise of stock options     (3,968,894)    (398,529)    (449,528)
          Noncash interest expense          128,800       71,933      273,714
          Net changes in assets and
           liabilities affecting operating
                   Accounts receivable   (3,047,238)    (755,810)   2,746,925
                   Inventory             (3,060,097)    (813,667)    (278,011)
                   Prepaid, other current
                    assets and other
                    assets                 (721,464)    (163,274)    (184,268)
                   Accounts payable and
                    other accrued
                    liabilities           6,572,098    1,652,911     (811,107)
                   Other long-term
                    obligations            (510,942)      42,501     (323,691)
                                           --------       ------     --------
                   Net cash provided by
                    operating activities    404,970    6,396,952    8,626,882
                                            -------    ---------    ---------
    Cash flows from investing activities:
      Additions to property and equipment  (601,802)     (67,572)    (152,420)
      Additions to trademarks and patents  (110,541)     (66,576)     (11,069)
                                           --------      -------      -------
                   Net cash used in
                    investing activities   (712,343)    (134,148)    (163,489)
                                           --------     --------     --------
    Cash flows from financing activities:
      Proceeds from initial public
       offering of common stock          85,000,000            -            -
      Costs of initial public offering   (7,479,011)    (687,977)  (2,031,416)
      Proceeds from borrowings on
       long-term debt                    18,000,000    4,083,340            -
      Principal payments on note
       payable                           (5,000,000)  (1,833,336)  (1,833,336)
      Net borrowings on line of credit            -      500,000      500,000
      Payment of other long-term
       obligations                                -   (2,760,000)  (1,500,000)
      Costs of financing for long-term
       debt and credit facility            (189,660)     (29,491)           -
      Payments made in connection with
       repurchase of common shares      (27,295,808)  (4,999,995)           -
      Proceeds from exercise of
       stock options                        175,089       81,159      510,951
      Excess tax benefit derived from
       exercise of stock options          3,968,894      398,529      449,528
                                          ---------      -------      -------
                   Net cash provided by
                    (used in) financing
                    activities           67,179,504   (5,247,771)  (3,904,273)
                                         ----------   ----------   ----------
                   Net increase in cash
                    and cash equivalents 66,872,131    1,015,033    4,559,120
    Cash and cash equivalents, beginning
     of year                             11,829,551   10,814,518    6,255,398
                                         ----------   ----------    ---------
    Cash and cash equivalents, end 
     of year                            $78,701,682  $11,829,551  $10,814,518
                                        ===========  ===========  ===========
    Supplemental disclosure of cash
     flow information:
      Cash paid during the year for:
        Interest                           $677,387     $221,000     $419,100
        Income taxes                        196,187    1,486,991       89,075
      Noncash investing and financing
        Deferred financing costs            335,075      125,000            -
        Increase in accounts payable
         and accrued expenses of initial
         public offering                          -            -      645,934

SOURCE Cumberland Pharmaceuticals Inc.

Back to top



SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 13th ... in Washington D.C. revolved around the fact that proper dental care, both at-home and ... the link between periodontal disease (more commonly referred to as gum disease) and diabetes. ...
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community ... 30 (see Table 1-1 ). More than 3.7 billion people under the age ... type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . , ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind ... mental health and wellness consultation, has collaborated with a leading web-based marketplace for ... gap experienced by parents and bring advice from parenting experts within their reach. ...
Breaking Medicine News(10 mins):